DRD2 and neoplasm: Interestingly, a recent preclinical study investigating the efficacy of the DRD2 antagonist Trifluoperazine (TFP) in colorectal cancer reported that tumors from TFP‐treated mice had increased tumor expression of PD‐L1, as well as increased PD‐1 expression on tumor‐infiltrating CD4+ and CD8+ T cells [68].